First Patient Dosed in Prokarium's PARADIGM-1 NMIBC Trial

Prokarium, a biopharmaceutical firm specializing in synthetic biology, has initiated a Phase I/Ib clinical trial, known as PARADIGM-1, for non-muscle invasive bladder cancer (NMIBC) patients. The first participant has received treatment with ZH9, an experimental immunotherapy being tested for safety and efficacy. The trial is taking place at various US locations and will assess a single intravesical dose of ZH9 under the same Investigational New Drug (IND) application.
Dr. Josefin-Beate Holz, Prokarium's Chief Medical Officer, expressed enthusiasm about the trial's commencement, highlighting its potential to improve NMIBC treatment. Dr. Daniel Zainfeld, a urologist from San Antonio, echoed the sentiment, noting the trial's significance for patients in need of novel therapeutic approaches. Kristen Albright, Prokarium's CEO, thanked the participants and medical professionals involved, emphasizing the company's commitment to developing "Living Cures" through synthetic biology.
Prokarium, headquartered in London, is focused on creating innovative, accessible immunotherapies. Their lead program, the subject of the PARADIGM-1 trial, is a single-dose therapy designed to revolutionize bladder cancer treatment. ZH9, the company's proprietary immunotherapy, is being investigated in the clinical trial to offer a new treatment option for NMIBC patients.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!